Search

Your search keyword '"Attali, Pierre"' showing total 31 results
Start Over Author "Attali, Pierre" Search Limiters Available in Library Collection
31 results on '"Attali, Pierre"'

1. Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis

Author

Nahon, Pierre, Asselah, Tarik, Guyader, Dominique, Pol, Stanislas, Fontaine, Hélène, Pageaux, Georges-Philippe, De Lédinghen, Victor, Ouzan, Denis, Zoulim, Fabien, Roulot, Dominique, Tran, Albert, Bronowicki, Jean-Pierre, Decaensi, Thomas, Riachi, Ghassan, Calès, Paul, Péron, Jean-Marie, Alric, Laurent, Bourlière, Marc, Mathurin, Philippe, Dharancy, Sebastien, Blanc, Jean-Frédéric, Abergel, Armand, Chazouillères, Olivier, Mallat, Ariane, Grangé, Jean-Didier, Attali, Pierre, d’Alteroche, Louis, Wartelle, Claire, Dao, Thông, Thabut, Dominique, Pilette, Christophe, Silvain, Christine, Christidis, Christos, Nguyen-Khac, Eric, Bernard-Chabert, Brigitte, Hillaire, Sophie, Di Martino, Vincent, Bonnet, Delphine, Payssan-Sicart, Virginie, Pomes, Chloe, Bailly, François, Beaudoin, Marjolaine, Giboz, Dominique, Hartig-Lavie, Kerstin, Maynard, Marianne, Billaud, Eric, Boutoille, David, Cavellec, Morane, Cheraud-Carpentier, Marjorie, Hubert, Isabelle, Benhida, Jaouad, Lannes, Adrien, Lunel, Françoise, Oberti, Frédéric, Boyer, Nathalie, Giuily, Nathalie, Castelnau, Corinne, Scoazec, Giovanna, Chibah, Aziza, Keser, Sylvie, Bonardi, Karim, Vallet-Pichard, Anaïs, Sogni, Philippe, Foucher, Juliette, Hiriart, Jean-Baptiste, Wilson, Amy, Shili, Sarah, Chermak, Faiza, Ansaldi, Christelle, Ben Amara, Nisserine, Chouquet, Laëtitia, De Luca, Emilie, Oules, Valérie, Anty, Rodolphe, Gelsi, Eve, Truchi, Régine, Luckina, Elena, Messaoudi, Nadia, Moussali, Joseph, De Dieuleveult, Barbara, Labarriere, Damien, Poter, Pascal, Si Ahmed, Si Nafa, Grando-Lemaire, Véronique, Bourcier, Valérie, Brulé, Séverine, Stalhberger, Thomas, Jezequel, Caroline, Brener, Audrey, Laligant, Anne, Rabot, Aline, Renard, Isabelle, Baumert, Thomas F., Dofföel, Michel, Mutter, Catherine, Simo-Noumbissie, Pauline, Razi, Esma, Barraud, Hélène, Bensenane, Mouni, Nani, Abdelbasset, Hassani-Nani, Sarah, Bernard, Marie-Albertine, Bismuth, Michael, Caillo, Ludovic, Faure, Stéphanie, Ripault, Marie Pierre, Bureau, Christophe, Peron, Jean Marie, Robic, Marie Angèle, Tarallo, Léa, Faure, Marine, Froissart, Bruno, Hilleret, Marie-Noelle, Zarski, Jean-Pierre, Goria, Odile, Grard, Victorien, Montialoux, Hélène, François, Muriel, Ouedraogo, Christian, Pauleau, Christelle, Varault, Anne, Andreani, Tony, Angoulevant, Bénédicte, Chevance, Azeline, Serfaty, Lawrence, Antonini, Teresa, Coilly, Audrey, Duclos Vallée, Jean-Charles, Tateo, Mariagrazia, Bonny, Corinne, Brigitte, Chanteranne, Lamblin, Géraldine, Muti, Léon, Babouri, Abdenour, Filipe, Virginie, Barrault, Camille, Costes, Laurent, Hagège, Hervé, Merbah, Soraya, Carrier, Paul, Debette-Gratien, Maryline, Jacques, Jérémie, Lassailly, Guillaume, Artu, Florent, Canva, Valérie, Dharancy, Sébastien, Louvet, Alexandre, Latournerie, Marianne, Bardou, Marc, Mouillot, Thomas, Bacq, Yannick, Barbereau, Didier, Nicolas, Charlotte, Chevalier, Caroline, Archambeaud, Isabelle, Habes, Sarah, Botta-Fridlund, Danièle, Saillard, Eric, Lafrance, Marie-Josée, Cacoub, Patrice, Carrat, Fabrice, Carrieri, Patrizia, Delarocque-Astagneau, Elisabeth, De Ledinghen, Victor, Dorival, Céline, Dubuisson, Jean, Housset, Chantal, Larrey, Dominique, Marcellin, Patrick, Pawlotsky, Jean-Michel, Petrov-Sanchez, Ventzislava, Vaux, Sophie, Wittkop, Linda, Yazdanpanah, Yazdan, Zucman-Rossi, Jessica, Ganne-Carrié, Nathalie, Chaffaut, Cendrine, Moreno, Christophe, Moirand, Romain, Carbonell, Nicolas, Duclos-Vallée, Jean-Charles, de Ledinghen, Victor, Ozenne, Violaine, Henrion, Jean, Perlemuter, Gabriel, Amiot, Xavier, Chevret, Sylvie, Najean, Marie, Layese, Richard, Zarca, Kevin, Segar, Laeticia Blampain, Cagnot, Carole, N’Kontchou, Gisèle, Ronot, Maxime, Audureau, Etienne, and Durand-Zaleski, Isabelle

Published
2022
Full Text
View/download PDF

2. Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance

Author

Ganne-Carrié, Nathalie, Chaffaut, Cendrine, Archambeaud, Isabelle, d’Alteroche, Louis, Oberti, Frédéric, Roulot, Dominique, Moreno, Christophe, Louvet, Alexandre, Dao, Thông, Moirand, Romain, Goria, Odile, Nguyen-Khac, Eric, Carbonell, Nicolas, Duclos-Vallée, Jean-Charles, Pol, Stanislas, de Ledinghen, Victor, Ozenne, Violaine, Henrion, Jean, Péron, Jean-Marie, Tran, Albert, Perlemuter, Gabriel, Amiot, Xavier, Zarski, Jean-Pierre, Chevret, Sylvie, Nahon, Pierre, Asselah, Tarik, Guyader, Dominique, Fontaine, Hélène, Pageaux, Georges-Philippe, De Lédinghen, Victor, Ouzan, Denis, Zoulim, Fabien, Bronowicki, Jean-Pierre, Decaens, Thomas, Riachi, Ghassan, Calès, Paul, Alric, Laurent, Bourlière, Marc, Mathurin, Philippe, Dharancy, Sebastien, Blanc, Jean-Frédéric, Abergel, Armand, Chazouillères, Olivier, Mallat, Ariane, Grangé, Jean-Didier, Attali, Pierre, Wartelle, Claire, Thabut, Dominique, Pilette, Christophe, Silvain, Christine, Christidis, Christos, Bernard-Chabert, Brigitte, Hillaire, Sophie, Di Martino, Vincent, N’Kontchou, Gisèle, Layese, Richard, and Audureau, Etienne

Published
2021
Full Text
View/download PDF

3. Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment

Author

Huvelin, Sylvie Sacher, Calès, Paul, Valla, Dominique, Bureau, Christophe, Olivier, Anne, Oberti, Frédéric, Boursier, Jérôme, Galmiche, Jean Paul, Vinel, Jean Pierre, Duburque, Clotilde, Attar, Alain, Archambeaud, Isabelle, Benamouzig, Robert, Gaudric, Marianne, Luet, Dominique, Couzigou, Patrice, Planche, Lucie, Coron, Emmanuel, Hiriart, Jean-Baptiste, Chermak, Faiza, Charbonnier, Maude, Nahon, Pierre, Marcellin, Patrick, Guyader, Dominique, Pol, Stanislas, Fontaine, Hélène, Larrey, Dominique, De Lédinghen, Victor, Ouzan, Denis, Zoulim, Fabien, Roulot, Dominique, Tran, Albert, Bronowicki, Jean-Pierre, Zarski, Jean-Pierre, Leroy, Vincent, Riachi, Ghassan, Péron, Jean-Marie, Alric, Laurent, Bourlière, Marc, Mathurin, Philippe, Dharancy, Sebastien, Blanc, Jean-Frédéric, Abergel, Armand, Serfaty, Lawrence, Mallat, Ariane, Grangé, Jean-Didier, Attali, Pierre, Bacq, Yannick, Wartelle, Claire, Dao, Thông, Benhamou, Yves, Pilette, Christophe, Silvain, Christine, Christidis, Christos, Capron, Dominique, Thiefin, Gérard, Hillaire, Sophie, Di Martino, Vincent, Berger, Arthur, Ravaioli, Federico, Farcau, Oana, Festi, Davide, Stefanescu, Horia, Buisson, François, Ganne-Carriè, Nathalie, Berzigotti, Annalisa, de Ledinghen, Victor, and Petta, Salvatore

Published
2021
Full Text
View/download PDF

4. Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy

Author

Nahon, Pierre, Marcellin, Patrick, Guyader, Dominique, Pol, Stanislas, Fontaine, Hélène, Larrey, Dominique, De Lédinghen, Victor, Ouzan, Denis, Zoulim, Fabien, Roulot, Dominique, Tran, Albert, Bronowicki, Jean-Pierre, Zarski, Jean-Pierre, Leroy, Vincent, Riachi, Ghassan, Calès, Paul, Péron, Jean-Marie, Alric, Laurent, Bourlière, Marc, Mathurin, Philippe, Dharancy, Sebastien, Blanc, Jean-Frédéric, Abergel, Armand, Serfaty, Lawrence, Mallat, Ariane, Grangé, Jean-Didier, Attali, Pierre, Bacq, Yannick, Wartelle, Claire, Dao, Thông, Thabut, Dominique, Pilette, Christophe, Silvain, Christine, Christidis, Christos, Capron, Dominique, Thiefin, Gérard, Hillaire, Sophie, Di Martino, Vincent, Bureau, Christophe, Layese, Richard, Bourcier, Valérie, Hammouche, Maryam, Cagnot, Carole, Goria, Odile, Wartelle-Bladou, Claire, Bernard-Chabert, Brigitte, Sutton, Angela, Audureau, Etienne, and Roudot-Thoraval, Françoise

Published
2019
Full Text
View/download PDF

5. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs

Author

Nahon, Pierre, Marcellin, Patrick, Guyader, Dominique, Pol, Stanislas, Fontaine, Hélène, Larrey, Dominique, De Lédinghen, Victor, Ouzan, Denis, Zoulim, Fabien, Roulot, Dominique, Tran, Albert, Bronowicki, Jean-Pierre, Zarski, Jean-Pierre, Leroy, Vincent, Riachi, Ghassan, Calès, Paul, Péron, Jean-Marie, Alric, Laurent, Bourlière, Marc, Mathurin, Philippe, Dharancy, Sebastien, Blanc, Jean-Frédéric, Abergel, Armand, Serfaty, Lawrence, Mallat, Ariane, Grangé, Jean-Didier, Attali, Pierre, Bacq, Yannick, Wartelle, Claire, Dao, Thông, Thabut, Dominique, Pilette, Christophe, Silvain, Christine, Christidis, Christos, Nguyen-Khac, Eric, Bernard-Chabert, Brigitte, Hillaire, Sophie, Di Martino, Vincent, Layese, Richard, Bourcier, Valérie, Cagnot, Carole, Zucman, David, Sutton, Angela, Roudot-Thoraval, Françoise, and Audureau, Etienne

Published
2018
Full Text
View/download PDF

6. Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study

Author

Nahon, Pierre, Marcellin, Patrick, Guyader, Dominique, Pol, Stanislas, Fontaine, Hélène, Larrey, Dominique, De Lédinghen, Victor, Ouzan, Denis, Zoulim, Fabien, Roulot, Dominique, Tran, Albert, Bronowicki, Jean-Pierre, Zarski, Jean-Pierre, Leroy, Vincent, Riachi, Ghassan, Calès, Paul, Péron, Jean-Marie, Alric, Laurent, Bourlière, Marc, Mathurin, Philippe, Dharancy, Sebastien, Blanc, Jean-Frédéric, Abergel, Armand, Serfaty, Lawrence, Mallat, Ariane, Grangé, Jean-Didier, Attali, Pierre, Bacq, Yannick, Wartelle, Claire, Dao, Thông, Thabut, Dominique, Pilette, Christophe, Silvain, Christine, Christidis, Christos, Capron, Dominique, Thiefin, Gérard, Hillaire, Sophie, Di Martino, Vincent, Costentin, Charlotte E., Layese, Richard, Bourcier, Valérie, Cagnot, Carole, Nguyen-khac, Eric, Bernard-Chabert, Brigitte, Zucman, David, Sutton, Angela, Letouzé, Eric, Imbeaud, Sandrine, Zucman-Rossi, Jessica, Audureau, Etienne, and Roudot-Thoraval, Françoise

Published
2018
Full Text
View/download PDF

7. Safety and efficacy of intra-arterial hepatic chemotherapy with doxorubicin-loaded nanoparticles in hepatocellular carcinoma

Author

Merle, Philippe, Camus, Philippe, Abergel, Armand, Pageaux, Georges Philippe, Masliah, Claude, Bronowicki, Jean Pierre, Zarski, Jean Pierre, Pelletier, Gilles, Bouattour, Mohamed, Farloux, Laetitia, Dorval, Etienne, verset, Gilles, Si-Ahmed, Si-Nafa, Doffoel, Michel, Couzigou, Patrice, Taieb, Julien, Vasseur, Bérangère, and Attali, Pierre

Published
2017
Full Text
View/download PDF

8. Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment

Author

Berger, Arthur, primary, Ravaioli, Federico, additional, Farcau, Oana, additional, Festi, Davide, additional, Stefanescu, Horia, additional, Buisson, François, additional, Nahon, Pierre, additional, Bureau, Christophe, additional, Ganne-Carriè, Nathalie, additional, Berzigotti, Annalisa, additional, de Ledinghen, Victor, additional, Petta, Salvatore, additional, Calès, Paul, additional, Huvelin, Sylvie Sacher, additional, Valla, Dominique, additional, Olivier, Anne, additional, Oberti, Frédéric, additional, Boursier, Jérôme, additional, Galmiche, Jean Paul, additional, Vinel, Jean Pierre, additional, Duburque, Clotilde, additional, Attar, Alain, additional, Archambeaud, Isabelle, additional, Benamouzig, Robert, additional, Gaudric, Marianne, additional, Luet, Dominique, additional, Couzigou, Patrice, additional, Planche, Lucie, additional, Coron, Emmanuel, additional, Hiriart, Jean-Baptiste, additional, Chermak, Faiza, additional, Charbonnier, Maude, additional, Marcellin, Patrick, additional, Guyader, Dominique, additional, Pol, Stanislas, additional, Fontaine, Hélène, additional, Larrey, Dominique, additional, De Lédinghen, Victor, additional, Ouzan, Denis, additional, Zoulim, Fabien, additional, Roulot, Dominique, additional, Tran, Albert, additional, Bronowicki, Jean-Pierre, additional, Zarski, Jean-Pierre, additional, Leroy, Vincent, additional, Riachi, Ghassan, additional, Péron, Jean-Marie, additional, Alric, Laurent, additional, Bourlière, Marc, additional, Mathurin, Philippe, additional, Dharancy, Sebastien, additional, Blanc, Jean-Frédéric, additional, Abergel, Armand, additional, Serfaty, Lawrence, additional, Mallat, Ariane, additional, Grangé, Jean-Didier, additional, Attali, Pierre, additional, Bacq, Yannick, additional, Wartelle, Claire, additional, Dao, Thông, additional, Benhamou, Yves, additional, Pilette, Christophe, additional, Silvain, Christine, additional, Christidis, Christos, additional, Capron, Dominique, additional, Thiefin, Gérard, additional, Hillaire, Sophie, additional, and Di Martino, Vincent, additional

Published
2021
Full Text
View/download PDF

9. Introduction

Author

Nucciarelli, Alberto, Attali, Pierre-Michel, and Baranes, Edmond

Subjects
Telecommunications industry, European Union
Abstract

Telecom liberalization progressively limited public intervention to the definition of a regulatory framework setting unbalanced market conditions to stimulate investments of new market players. However, a new impulse to public [...]

Published
2013

10. Local authorities & FTTx: what role for local players?

Author

Attali, Pierre-Michel

Subjects
Telecommunications industry
Abstract

Based on a panorama of network deployments by local authorities worldwide, this report allows the reader to understand the opportunity FTTx represents for local authorities and which are the principal [...]

Published
2009

11. Safety, tolerability, pharmacokinetics and pharmacokinetic-pharmacodynamic modelling of the novel H 4 receptor inhibitor SENS-111 using a modified caloric test in healthy subjects

Author

Venail, Frederic, Attali, Pierre, Wersinger, Eric, Gomeni, Roberto, Poli, Sonia, Schmerber, Sébastien, Service d'ORL, Hôpital Gui de Chauliac (CHRU de Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut des Neurosciences de Montpellier - Déficits sensoriels et moteurs (INM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Service d'Oto-Rhino-Laryngologie, and CHU Grenoble

Subjects
Adult, Male, Adolescent, Histamine Antagonists, Original Articles, Middle Aged, Models, Biological, Healthy Volunteers, vertigo, vestibular disorders, Young Adult, Pyrimidines, Double-Blind Method, type-4 histamine receptor, Caloric Tests, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Azetidines, Humans, pharmacokinetics/pharmacodynamics, Receptors, Histamine H4, nystagmus
Abstract

International audience; AIM:A Phase 1 study was performed to evaluate safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the selective histamine H4 receptor antagonist SENS-111, an oral small molecule.METHODS:One hundred healthy subjects were randomized in a placebo-controlled, double-blind study evaluating single-ascending doses (SAD; 100-500 mg) and multiple-ascending doses (MAD; 50-150 mg day-1 , 4 days; 200-250 mg day-1 , 7 days). Effects of SENS-111 on nystagmus and vertigo induced by modified caloric tests were measured in the MAD studies. Population PK and PK/PD models were developed using a nonlinear mixed-effects approach.RESULTS:SENS-111 was well tolerated with mild to moderate events. No sedation was reported. A maximal tolerated dose was not reached. Dose-proportional increases in concentrations were seen up to 200 mg and more than dose-proportional thereafter, with mean half-life between 24 and 56 h. The caloric test induced mild but measurable vertigo and nystagmus with large intra/inter-individual variation for all parameters. SENS-111 did not significantly impact nystagmus but significantly improved latency of vertigo appearance/disappearance, duration and European Evaluation of Vertigo questionnaire parameters vs. baseline. A two-compartment model with first-order absorption, distribution and elimination best fit the data. PK/PD indirect modelling applied to vertigo duration and latency of appearance indicated maximum activity between 100 and 500 ng ml-1 plasma concentrations, corresponding to 100 and 200 mg day-1 , which are appropriate for clinical efficacy evaluations in vestibular diseases.CONCLUSIONS:SENS-111 is a well-tolerated first-in-class H4 receptor antagonist with acceptable PK for oral daily dosing. PK/PD modelling determined plasma concentrations and doses for efficacy studies in patients with vertigo symptoms.

Published
2018

12. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial.

Author

UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie, Merle, Philippe, Blanc, Jean-Frederic, Phelip, Jean-Marc, Pelletier, Gilles, Bronowicki, Jean-Pierre, Touchefeu, Yann, Pageaux, Georges, Gerolami, René, Habersetzer, François, Nguyen-Khac, Eric, Casadei-Gardini, Andrea, Borbath, Ivan, Tran, Albert, Wege, Henning, Saad, Amr Shafik, Colombo, Massimo, Abergel, Armand, Richou, Carine, Waked, Imam, Yee, Nelson S, Molé, Audrey, Attali, Pierre, Le Boulicaut, Julie, Vasseur, Bérangère, RELIVE Investigators, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie, Merle, Philippe, Blanc, Jean-Frederic, Phelip, Jean-Marc, Pelletier, Gilles, Bronowicki, Jean-Pierre, Touchefeu, Yann, Pageaux, Georges, Gerolami, René, Habersetzer, François, Nguyen-Khac, Eric, Casadei-Gardini, Andrea, Borbath, Ivan, Tran, Albert, Wege, Henning, Saad, Amr Shafik, Colombo, Massimo, Abergel, Armand, Richou, Carine, Waked, Imam, Yee, Nelson S, Molé, Audrey, Attali, Pierre, Le Boulicaut, Julie, Vasseur, Bérangère, and RELIVE Investigators

Abstract

BACKGROUND: Cytotoxic chemotherapy is generally ineffective in patients with hepatocellular carcinoma. We assessed the intravenous perfusion of doxorubicin-loaded nanoparticles in patients with hepatocellular carcinoma in whom previous sorafenib therapy had failed. METHODS: We did a multicentre, open-label, randomised, controlled phase 3 trial at 70 sites in 11 countries. Patients with hepatocellular carcinoma with one or more previous systemic therapies, including sorafenib, were randomly assigned to receive 30 mg/m2 doxorubicin-loaded nanoparticles (30 mg/m2 group), 20 mg/m2 doxorubicin-loaded nanoparticles (20 mg/m2 group), or standard care using a computer-generated randomisation list prepared by the funder and stratified by geographic region. Patients in the experimental groups received perfusion of the drug every 4 weeks and those in the control group received any systemic anticancer therapy (except sorafenib) as per investigator decision. The primary endpoint was overall survival in the intention-to-treat population. Safety was assessed in the population of patients who received at least one dose of their assigned treatment. This trial is registered with ClinicalTrials.gov, number NCT01655693. FINDINGS: Between June 15, 2012, and Jan 27, 2017, 541 patients were screened, of whom 144 were excluded and 397 were randomly assigned to one of the groups (133 to the 30 mg/m2 group; 130 to the 20 mg/m2 group; and 134 to the control group). Median follow-up was 22·7 months (IQR 11·2-34·9). After pooling the doxorubicin groups for the efficacy analysis, median overall survival was 9·1 months (95% CI 8·1-10·4) in the pooled doxorubicin-loaded nanoparticles group and 9·0 months (7·1-11·8) in the control group (HR 1·00 [95% CI 0·78-1·28], two-sided p=0·99). 227 (94%) of 242 patients who received doxorubicin-loaded nanoparticles and 100 (75%) of 134 patients in the control group had at least one treatment-emergent adverse event. The most common drug-related grade 3 or 4 tr

Published
2019

15. Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy

Author

Thabut, Dominique, primary, Bureau, Christophe, additional, Layese, Richard, additional, Bourcier, Valérie, additional, Hammouche, Maryam, additional, Cagnot, Carole, additional, Marcellin, Patrick, additional, Guyader, Dominique, additional, Pol, Stanislas, additional, Larrey, Dominique, additional, De Lédinghen, Victor, additional, Ouzan, Denis, additional, Zoulim, Fabien, additional, Roulot, Dominique, additional, Tran, Albert, additional, Bronowicki, Jean-Pierre, additional, Zarski, Jean-Pierre, additional, Goria, Odile, additional, Calès, Paul, additional, Péron, Jean-Marie, additional, Alric, Laurent, additional, Bourlière, Marc, additional, Mathurin, Philippe, additional, Blanc, Jean-Frédéric, additional, Abergel, Armand, additional, Serfaty, Lawrence, additional, Mallat, Ariane, additional, Grangé, Jean-Didier, additional, Attali, Pierre, additional, Bacq, Yannick, additional, Wartelle-Bladou, Claire, additional, Dao, Thông, additional, Pilette, Christophe, additional, Silvain, Christine, additional, Christidis, Christos, additional, Capron, Dominique, additional, Bernard-Chabert, Brigitte, additional, Hillaire, Sophie, additional, Di Martino, Vincent, additional, Sutton, Angela, additional, Audureau, Etienne, additional, Roudot-Thoraval, Françoise, additional, Nahon, Pierre, additional, Fontaine, Hélène, additional, Leroy, Vincent, additional, Riachi, Ghassan, additional, Dharancy, Sebastien, additional, Wartelle, Claire, additional, Thabut, Dominique, additional, and Thiefin, Gérard, additional

Published
2019
Full Text
View/download PDF

16. The French case

Author

Attali, Pierre-Michel

Subjects
Telecommunications industry
Abstract

While this issue of Communications & Strategies provides a detailed description of the various forms of public intervention in Australia, New Zealand or Ghana, it should be noted that public [...]

Published
2013

18. Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study

Author

Costentin, Charlotte E., primary, Layese, Richard, additional, Bourcier, Valérie, additional, Cagnot, Carole, additional, Marcellin, Patrick, additional, Guyader, Dominique, additional, Pol, Stanislas, additional, Larrey, Dominique, additional, De Lédinghen, Victor, additional, Ouzan, Denis, additional, Zoulim, Fabien, additional, Roulot, Dominique, additional, Tran, Albert, additional, Bronowicki, Jean-Pierre, additional, Zarski, Jean-Pierre, additional, Riachi, Ghassan, additional, Calès, Paul, additional, Péron, Jean-Marie, additional, Alric, Laurent, additional, Bourlière, Marc, additional, Mathurin, Philippe, additional, Blanc, Jean-Frédéric, additional, Abergel, Armand, additional, Serfaty, Lawrence, additional, Mallat, Ariane, additional, Grangé, Jean-Didier, additional, Attali, Pierre, additional, Bacq, Yannick, additional, Wartelle, Claire, additional, Dao, Thông, additional, Thabut, Dominique, additional, Pilette, Christophe, additional, Silvain, Christine, additional, Christidis, Christos, additional, Nguyen-khac, Eric, additional, Bernard-Chabert, Brigitte, additional, Zucman, David, additional, Di Martino, Vincent, additional, Sutton, Angela, additional, Letouzé, Eric, additional, Imbeaud, Sandrine, additional, Zucman-Rossi, Jessica, additional, Audureau, Etienne, additional, Roudot-Thoraval, Françoise, additional, Nahon, Pierre, additional, Fontaine, Hélène, additional, Leroy, Vincent, additional, Dharancy, Sebastien, additional, Capron, Dominique, additional, Thiefin, Gérard, additional, and Hillaire, Sophie, additional

Published
2018
Full Text
View/download PDF

19. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications

Author

Nahon, Pierre, primary, Bourcier, Valérie, additional, Layese, Richard, additional, Audureau, Etienne, additional, Cagnot, Carole, additional, Marcellin, Patrick, additional, Guyader, Dominique, additional, Fontaine, Hélène, additional, Larrey, Dominique, additional, De Lédinghen, Victor, additional, Ouzan, Denis, additional, Zoulim, Fabien, additional, Roulot, Dominique, additional, Tran, Albert, additional, Bronowicki, Jean-Pierre, additional, Zarski, Jean-Pierre, additional, Leroy, Vincent, additional, Riachi, Ghassan, additional, Calès, Paul, additional, Péron, Jean-Marie, additional, Alric, Laurent, additional, Bourlière, Marc, additional, Mathurin, Philippe, additional, Dharancy, Sébastien, additional, Blanc, Jean-Frédéric, additional, Abergel, Armand, additional, Serfaty, Lawrence, additional, Mallat, Ariane, additional, Grangé, Jean-Didier, additional, Attali, Pierre, additional, Bacq, Yannick, additional, Wartelle, Claire, additional, Dao, Thông, additional, Benhamou, Yves, additional, Pilette, Christophe, additional, Silvain, Christine, additional, Christidis, Christos, additional, Capron, Dominique, additional, Bernard-Chabert, Brigitte, additional, Zucman, David, additional, Di Martino, Vincent, additional, Thibaut, Vincent, additional, Salmon, Dominique, additional, Ziol, Marianne, additional, Sutton, Angela, additional, Pol, Stanislas, additional, Roudot-Thoraval, Françoise, additional, Nahon, Pierre, additional, Thiefin, Gérard, additional, and Hillaire, Sophie, additional

Published
2017
Full Text
View/download PDF

20. Safety, tolerability, pharmacokinetics and pharmacokinetic‐pharmacodynamic modelling of the novel H4 receptor inhibitor SENS‐111 using a modified caloric test in healthy subjects.

Author

Venail, Frédéric, Attali, Pierre, Wersinger, Eric, Gomeni, Roberto, Poli, Sonia, and Schmerber, Sebastien

Subjects
*PHARMACOKINETICS, *PHARMACODYNAMICS, *HISTAMINE receptors, *ANTIHISTAMINES, *NYSTAGMUS
Abstract

Aim: A Phase 1 study was performed to evaluate safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the selective histamine H4 receptor antagonist SENS‐111, an oral small molecule. Methods: One hundred healthy subjects were randomized in a placebo‐controlled, double‐blind study evaluating single‐ascending doses (SAD; 100–500 mg) and multiple‐ascending doses (MAD; 50–150 mg day−1, 4 days; 200–250 mg day−1, 7 days). Effects of SENS‐111 on nystagmus and vertigo induced by modified caloric tests were measured in the MAD studies. Population PK and PK/PD models were developed using a nonlinear mixed‐effects approach. Results: SENS‐111 was well tolerated with mild to moderate events. No sedation was reported. A maximal tolerated dose was not reached. Dose‐proportional increases in concentrations were seen up to 200 mg and more than dose‐proportional thereafter, with mean half‐life between 24 and 56 h. The caloric test induced mild but measurable vertigo and nystagmus with large intra/inter‐individual variation for all parameters. SENS‐111 did not significantly impact nystagmus but significantly improved latency of vertigo appearance/disappearance, duration and European Evaluation of Vertigo questionnaire parameters vs. baseline. A two‐compartment model with first‐order absorption, distribution and elimination best fit the data. PK/PD indirect modelling applied to vertigo duration and latency of appearance indicated maximum activity between 100 and 500 ng ml−1 plasma concentrations, corresponding to 100 and 200 mg day−1, which are appropriate for clinical efficacy evaluations in vestibular diseases. Conclusions: SENS‐111 is a well‐tolerated first‐in‐class H4 receptor antagonist with acceptable PK for oral daily dosing. PK/PD modelling determined plasma concentrations and doses for efficacy studies in patients with vertigo symptoms. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

21. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis

Author

Hézode, Christophe, Fontaine, Hélène, Dorival, Céline, Zoulim, Fabien, Larrey, Dominique, Canva, Valérie, de Ledinghen, Victor, Poynard, Thierry, Samuel, Didier, Bourlière, Marc, Alric, Laurent, Raabe, Jean-Jacques, Zarski, Jean-Pierre, Marcellin, Patrick, Riachi, Ghassan, Bernard, Pierre-Henri, Loustaud-Ratti, Véronique, Chazouillères, Olivier, Abergel, Armand, Guyader, Dominique, Métivier, Sophie, Tran, Albert, Di Martino, Vincent, Causse, Xavier, Dao, Thong, Lucidarme, Damien, Portal, Isabelle, Cacoub, Patrice, Gournay, Jérôme, Grando-Lemaire, Véronique, Hillon, Patrick, Attali, Pierre, Fontanges, Thierry, Rosa, Isabelle, Petrov-Sanchez, Ventzislava, Barthe, Yoann, Pawlotsky, Jean-Michel, Pol, Stanislas, Carrat, Fabrice, Bronowicki, Jean-Pierre, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service d'hépato-gastro-entérologie [APHP Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service d'hépatologie médicale [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Epidémiologie, Systèmes d'Information, Modélisation, Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Cellules souches normales et cancéreuses, Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Service des Maladies de l'Appareil Digestif et de la Nutrition [CHRU Lille], Hôpital Claude Huriez [Lille], CHU Lille-CHU Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Physiopathologie du cancer du foie, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Bordeaux [Bordeaux], Service d'Hépato-Gastro-Entérologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de Recherche Saint-Antoine (UMRS893), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Pathogénèse et traitement de l'hépatite fulminante et du cancer du foie, Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'hépatologie et de gastroentérologie [Hôpital Saint-Joseph - Marseille], Aix Marseille Université (AMU)-Hôpital Saint-Joseph [Marseille], Pharmacochimie et Biologie pour le Développement (PHARMA-DEV), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT-FR 2599), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville), Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), Département d'hépato-gastroentérologie, CHU Grenoble-Université Grenoble Alpes (UGA), Service d'hépatologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de recherche biomédicale Bichat-Beaujon (CRB3), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service d'Hépato-Gastro-Entérologie, CHU Bordeaux [Bordeaux]-Hôpital Saint-André, Service d'Hépato-Gastro-Entérologie et Nutrition [CHU Limoges], CHU Limoges, Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques (RESINFIT), CHU Limoges-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Service d'hépatologie [CHU Saint-Antoine], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Image Science for Interventional Techniques (ISIT), Université d'Auvergne - Clermont-Ferrand I (UdA)-Clermont Université-Centre National de la Recherche Scientifique (CNRS), Service d'Hépato-gastro-entérologie [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Foie, métabolismes et cancer, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service de Gastro-entérologie - Hépatologie [Purpan], CHU Toulouse [Toulouse], Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Régional d'Orléans (CHRO), Service d'Hépato-Gastro-Enterologie et Nutrition [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Mobilités : Attention, Orientation et Chronobiologie (COMETE), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Groupe Hospitalier de l'Institut Catholique de Lille (GHICL), Université catholique de Lille (UCL), Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Service de médecine interne [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Immunologie - Immunopathologie - Immunothérapeutique (I3), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôtel-Dieu de Nantes, Hôpital Jean Verdier [AP-HP], Service d'Hépato-Gastro-Entérologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service d'hépato-gastro-entérologie, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, CH Pierre Oudot Bourgoin-Jallieu, Centre Hospitalier Intercommunal de Créteil (CHIC), Pôle de Pharmacie - Santé Publique - Information médicale [CHU Saint-Antoine], Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), This study was sponsored and funded by The National Agency for Research on AIDS and Viral Hepatitis (ANRS).The ANRS C020 CUPIC cohort study was conducted with the support and participation of the Association Française pour l'Etude du Foie (AFEF), CUPIC STUDY GROUP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Pôle Maladies de l'appareil digestif [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Services d'hépatologie, Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-CHU Saint-Eloi, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), Hôpital Huriez-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Bordeaux [Bordeaux]-Hôpital Haut-Lévêque [CHU Bordeaux], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance Publique - Hôpitaux de Marseille (APHM), Service de médecine interne et maladies digestives, Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC), Service d'Hépato-gastro-entérologie [CHR Metz-Thionville], Université Grenoble Alpes (UGA)-CHU Grenoble, Hôpital Charles Nicolle [Rouen]-Université de Rouen Normandie (UNIROUEN), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-CHU Limoges, Service d'hépatologie [Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Université Pierre et Marie Curie - Paris 6 (UPMC), CHU Etaing, Service des maladies du foie, Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CHU Pontchaillou [Rennes], CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], Département digestif, Centre Hospitalier Universitaire de Nice (CHU Nice), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service Hépato-gastro-entérologie et oncologie digestive [CHR Orléans], Groupe Hospitalier de l'Institut Catholique Lillois, Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Hôpital Hôtel-Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre hospitalier universitaire de Nantes (CHU Nantes), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris 13 (UP13)-Hôpital Jean Verdier [AP-HP], Hôpital Bicêtre-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11), CHI Créteil, Recherches fondamentales, cliniques et thérapeutiques sur les hépatites virales, ANRS France Recherche Nord & sud Sida-hiv hépatites, Centre National de Référence Virus des hépatites B, C et Delta, and Pôle de Pharmacie - Santé Publique - Information médicale [Saint-Antoine]

Subjects
cirrhosis, boceprevir, chronic hepatitis C, telaprevir, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology
Abstract

International audience; BACKGROUND & AIMS: We investigated the effectiveness of the protease inhibitors peginterferon and ribavirin in treatment-experienced patients with hepatitis C virus (HCV) genotype 1 infection and cirrhosis. METHODS: In the Compassionate Use of Protease Inhibitors in Viral C Cirrhosis study, 511 patients with HCV genotype 1 infection and compensated cirrhosis who did not respond to a prior course of peginterferon and ribavirin (44.3% relapsers or patients with viral breakthrough, 44.8% partial responders, and 8.0% null responders) were given either telaprevir (n = 299) or boceprevir (n = 212) for 48 weeks. We assessed percentages of patients with sustained viral responses 12 weeks after therapy and safety. This observational study did not allow for direct comparison of the 2 regimens. RESULTS: Among patients given telaprevir, 74.2% of relapsers, 40.0% of partial responders, and 19.4% of null responders achieved SVR12. Among those given boceprevir, 53.9% of relapsers, 38.3% of partial responders, and none of the null responders achieved SVR12. In multivariate analysis, factors associated with SVR12 included prior response to treatment response, no lead-in phase, HCV subtype 1b (vs 1a), and baseline platelet count greater than 100,000/mm(3). Severe adverse events occurred in 49.9% of cases, including liver decompensation, severe infections in 10.4%, and death in 2.2%. In multivariate analysis, baseline serum albumin level less than 35 g/L and baseline platelet counts of 100,000/mm(3) or less predicted severe side effects or death. CONCLUSIONS: Relatively high percentages of real-life, treatment-experienced patients with HCV genotype 1 infection and cirrhosis respond to the combination of peginterferon and ribavirin with telaprevir or boceprevir. However, side effects are frequent and often severe. Baseline levels of albumin and platelet counts can be used to guide treatment decisions. ClinicalTrials.gov number: NCT01514890.

Published
2014

22. 0436: Diagnostic value of serial ultrasensible troponin I measurements for acute coronary syndrome identification in cardiac intensive care unit

Author

Hopp, Ozlem, primary, Kremer, Helene, additional, Messas, Nathan, additional, Crimizade, Ulun, additional, Hess, Sebastien, additional, Samet, Hafida, additional, Lavaux, Thomas, additional, Jesel, Laurence, additional, Attali, Pierre, additional, Harscoat, Sébastien, additional, Bilbault, Pascal, additional, Olivier, Morel, additional, and Ohlmann, Patrick, additional

Published
2014
Full Text
View/download PDF

23. Authors' reply

Author

Attali, Pierre

Subjects
Authors' Replies, General Medicine, Cardiology and Cardiovascular Medicine
Published
1999

24. Hereditary persistence of α-fetoprotein is due to both proximal and distal hepatocyte nuclear factor-1 site mutations 1 1The authors thank Dr. A. Chauchereau for the gift of A9TKCAT vector, Dr. O. Lahuna for helpful discussion, C. Aumas for excellent technical assistance, and S. Wenk for careful English proofreading of the text. We are grateful for the cooperation of the patients and their families.

Author

Alj, Youssef, primary, Georgiakaki, Maria, additional, Savouret, Jean-François, additional, Mal, FrÉdÉric, additional, Attali, Pierre, additional, Pelletier, Gilles, additional, Fourré, Catherine, additional, Milgrom, Edwin, additional, Buffet, Catherine, additional, Guiochon-Mantel, Anne, additional, and Perlemuter, Gabriel, additional

Published
2004
Full Text
View/download PDF

25. Comparative Efficacy of a Two-Hour Regimen of Streptokinase Versus Alteplase in Acute Massive Pulmonary Embolism: Immediate Clinical and Hemodynamic Outcome and One-Year Follow-Up 11This study was partly supported by grants from Programme Hospitalier de la Recherche Clinique (Ministère de la Santé Publique), Paris; Boehringer Ingelheim, Reims Cedex, France; and Hoechst France, Puteaux, France.

Author

Meneveau, Nicolas, primary, Schiele, François, additional, Metz, Damien, additional, Valette, Benoît, additional, Attali, Pierre, additional, Vuillemenot, Alain, additional, Grollier, Gilles, additional, Elaerts, Jacques, additional, Mossard, Jean-Marie, additional, Viel, Jean-François, additional, and Bassand, Jean-Pierre, additional

Published
1998
Full Text
View/download PDF

27. Local authorities & FTTx.

Author

ATTALI, Pierre-Michel

Subjects
BROADBAND communication systems, COMPUTER network architectures, BANDWIDTHS, MODEMS, BUSINESS partnerships, BUSINESS models, ASYMMETRIC digital subscriber lines, LOCAL officials & employees
Abstract

The article discusses the application of fiber to the x (FTTx) by local authorities in businesses. It states that local authorities can intervene in FTTz projects through a partly state-owned player they control or through a private partner which manages the service provided in a business. Most Swedish and European public officials employ neutral Open Access Networks (OANs) which provide bandwidth to service operators while Asian authorities such as those in Japan and South Korea have optical fiber gradually supplanting Asymmetric Digital Subscriber Line (ADSL) and cable modem. It also tackles the strengths and weaknesses of local authorities when carrying out major FTTx projects.

Published
2009

28. Hereditary persistence of α-fetoprotein is due to both proximal and distal hepatocyte nuclear factor-1 site mutations11The authors thank Dr. A. Chauchereau for the gift of A9TKCAT vector, Dr. O. Lahuna for helpful discussion, C. Aumas for excellent technical assistance, and S. Wenk for careful English proofreading of the text. We are grateful for the cooperation of the patients and their families.

Author

Alj, Youssef, Georgiakaki, Maria, Savouret, Jean-François, Mal, FrÉdÉric, Attali, Pierre, Pelletier, Gilles, Fourré, Catherine, Milgrom, Edwin, Buffet, Catherine, Guiochon-Mantel, Anne, and Perlemuter, Gabriel

Abstract

Background & Aims:The molecular mechanism of hereditary persistence of α-fetoprotein (HPAFP) has been previously described in a large Scottish family, consisting of a −119G>A substitution in the distal hepatocyte nuclear factor 1 (HNF-1) binding site of the α-fetoprotein (AFP) gene promoter. We report here the molecular mechanisms of HPAFP in 2 new unrelated families. Methods:Family 1 was of Bengali origin, and family 2 was Italian. Four of 5 subjects (family 1) and 3 of 9 (family 2) showed HPAFP. The AFP gene promoter was studied in all available family members. Results:All subjects with high AFP levels had mutated promoter sequences. Family 1 showed the reported −119G>A substitution. Family 2 showed −55C>A and −65C>T substitutions in the proximal putative HNF-1 binding region of the promoter. The −55C>A mutation increased the similarity of the proximal HNF-1 binding region to a consensus binding region. Gel shift assays confirmed its increased affinity toward HNF-1, and transfection experiments revealed an increased level of gene transcription. The −65C>T substitution theoretically created a CCAAT box. However, gel shift and transfection experiments failed to show any biological effect of this substitution that is associated with the −55C>A mutation. Conclusions:Two different mutations localized in either HNF-1 binding sites of the AFP gene promoter may result in HPAFP. This highlights the importance of HNF-1 in AFP gene expression. Unexplained persistent AFP should lead to family study and/or AFP gene promoter sequencing to avoid inappropriate explorations and treatment decisions.

Published
2004
Full Text
View/download PDF

29. Safety, tolerability, pharmacokinetics and pharmacokinetic-pharmacodynamic modelling of the novel H 4 receptor inhibitor SENS-111 using a modified caloric test in healthy subjects.

Author

Venail F, Attali P, Wersinger E, Gomeni R, Poli S, and Schmerber S

Subjects
Adolescent, Adult, Azetidines pharmacokinetics, Azetidines pharmacology, Double-Blind Method, Healthy Volunteers, Histamine Antagonists pharmacokinetics, Histamine Antagonists pharmacology, Humans, Male, Middle Aged, Models, Biological, Pyrimidines pharmacokinetics, Pyrimidines pharmacology, Vertigo drug therapy, Young Adult, Azetidines adverse effects, Caloric Tests, Histamine Antagonists adverse effects, Pyrimidines adverse effects, Receptors, Histamine H4 antagonists & inhibitors
Abstract

Aim: A Phase 1 study was performed to evaluate safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the selective histamine H 4 receptor antagonist SENS-111, an oral small molecule., Methods: One hundred healthy subjects were randomized in a placebo-controlled, double-blind study evaluating single-ascending doses (SAD; 100-500 mg) and multiple-ascending doses (MAD; 50-150 mg day -1 , 4 days; 200-250 mg day -1 , 7 days). Effects of SENS-111 on nystagmus and vertigo induced by modified caloric tests were measured in the MAD studies. Population PK and PK/PD models were developed using a nonlinear mixed-effects approach., Results: SENS-111 was well tolerated with mild to moderate events. No sedation was reported. A maximal tolerated dose was not reached. Dose-proportional increases in concentrations were seen up to 200 mg and more than dose-proportional thereafter, with mean half-life between 24 and 56 h. The caloric test induced mild but measurable vertigo and nystagmus with large intra/inter-individual variation for all parameters. SENS-111 did not significantly impact nystagmus but significantly improved latency of vertigo appearance/disappearance, duration and European Evaluation of Vertigo questionnaire parameters vs. baseline. A two-compartment model with first-order absorption, distribution and elimination best fit the data. PK/PD indirect modelling applied to vertigo duration and latency of appearance indicated maximum activity between 100 and 500 ng ml -1 plasma concentrations, corresponding to 100 and 200 mg day -1 , which are appropriate for clinical efficacy evaluations in vestibular diseases., Conclusions: SENS-111 is a well-tolerated first-in-class H 4 receptor antagonist with acceptable PK for oral daily dosing. PK/PD modelling determined plasma concentrations and doses for efficacy studies in patients with vertigo symptoms., (© 2018 The British Pharmacological Society.)

Published
2018
Full Text
View/download PDF

30. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.

Author

Hézode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, De Ledinghen V, Poynard T, Samuel D, Bourliere M, Alric L, Raabe JJ, Zarski JP, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Chazouilleres O, Abergel A, Guyader D, Metivier S, Tran A, Di Martino V, Causse X, Dao T, Lucidarme D, Portal I, Cacoub P, Gournay J, Grando-Lemaire V, Hillon P, Attali P, Fontanges T, Rosa I, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, and Bronowicki JP

Subjects
Adult, Aged, Aged, 80 and over, Antiviral Agents adverse effects, Cohort Studies, Comorbidity, Drug Therapy, Combination, Female, Follow-Up Studies, Hepatitis C, Chronic epidemiology, Hepatitis C, Chronic virology, Humans, Interferon-alpha therapeutic use, Liver Cirrhosis epidemiology, Liver Cirrhosis virology, Male, Middle Aged, Multivariate Analysis, Oligopeptides adverse effects, Polyethylene Glycols therapeutic use, Proline adverse effects, Proline therapeutic use, Prospective Studies, Recombinant Proteins therapeutic use, Ribavirin therapeutic use, Treatment Failure, Treatment Outcome, Antiviral Agents therapeutic use, Genotype, Hepacivirus genetics, Hepatitis C, Chronic drug therapy, Liver Cirrhosis drug therapy, Oligopeptides therapeutic use, Proline analogs & derivatives
Abstract

Background & Aims: We investigated the effectiveness of the protease inhibitors peginterferon and ribavirin in treatment-experienced patients with hepatitis C virus (HCV) genotype 1 infection and cirrhosis., Methods: In the Compassionate Use of Protease Inhibitors in Viral C Cirrhosis study, 511 patients with HCV genotype 1 infection and compensated cirrhosis who did not respond to a prior course of peginterferon and ribavirin (44.3% relapsers or patients with viral breakthrough, 44.8% partial responders, and 8.0% null responders) were given either telaprevir (n = 299) or boceprevir (n = 212) for 48 weeks. We assessed percentages of patients with sustained viral responses 12 weeks after therapy and safety. This observational study did not allow for direct comparison of the 2 regimens., Results: Among patients given telaprevir, 74.2% of relapsers, 40.0% of partial responders, and 19.4% of null responders achieved SVR12. Among those given boceprevir, 53.9% of relapsers, 38.3% of partial responders, and none of the null responders achieved SVR12. In multivariate analysis, factors associated with SVR12 included prior response to treatment response, no lead-in phase, HCV subtype 1b (vs 1a), and baseline platelet count greater than 100,000/mm(3). Severe adverse events occurred in 49.9% of cases, including liver decompensation, severe infections in 10.4%, and death in 2.2%. In multivariate analysis, baseline serum albumin level less than 35 g/L and baseline platelet counts of 100,000/mm(3) or less predicted severe side effects or death., Conclusions: Relatively high percentages of real-life, treatment-experienced patients with HCV genotype 1 infection and cirrhosis respond to the combination of peginterferon and ribavirin with telaprevir or boceprevir. However, side effects are frequent and often severe. Baseline levels of albumin and platelet counts can be used to guide treatment decisions. ClinicalTrials.gov number: NCT01514890., (Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.)

Published
2014
Full Text
View/download PDF

31. Hereditary persistence of alpha-fetoprotein is due to both proximal and distal hepatocyte nuclear factor-1 site mutations.

Author

Alj Y, Georgiakaki M, Savouret JF, Mal F, Attali P, Pelletier G, Fourré C, Milgrom E, Buffet C, Guiochon-Mantel A, and Perlemuter G

Subjects
Base Sequence genetics, Binding Sites genetics, Hepatocyte Nuclear Factor 1, Hepatocyte Nuclear Factor 1-alpha, Hepatocyte Nuclear Factor 1-beta, Humans, Male, Middle Aged, Molecular Sequence Data, Pedigree, Promoter Regions, Genetic genetics, Promoter Regions, Genetic physiology, DNA-Binding Proteins, Mutation physiology, Nuclear Proteins, Transcription Factors metabolism, alpha-Fetoproteins genetics, alpha-Fetoproteins metabolism
Abstract

Background and Aims: The molecular mechanism of hereditary persistence of alpha-fetoprotein (HPAFP) has been previously described in a large Scottish family, consisting of a -119G>A substitution in the distal hepatocyte nuclear factor 1 (HNF-1) binding site of the alpha-fetoprotein (AFP) gene promoter. We report here the molecular mechanisms of HPAFP in 2 new unrelated families., Methods: Family 1 was of Bengali origin, and family 2 was Italian. Four of 5 subjects (family 1) and 3 of 9 (family 2) showed HPAFP. The AFP gene promoter was studied in all available family members., Results: All subjects with high AFP levels had mutated promoter sequences. Family 1 showed the reported -119G>A substitution. Family 2 showed -55C>A and -65C>T substitutions in the proximal putative HNF-1 binding region of the promoter. The -55C>A mutation increased the similarity of the proximal HNF-1 binding region to a consensus binding region. Gel shift assays confirmed its increased affinity toward HNF-1, and transfection experiments revealed an increased level of gene transcription. The -65C>T substitution theoretically created a CCAAT box. However, gel shift and transfection experiments failed to show any biological effect of this substitution that is associated with the -55C>A mutation., Conclusions: Two different mutations localized in either HNF-1 binding sites of the AFP gene promoter may result in HPAFP. This highlights the importance of HNF-1 in AFP gene expression. Unexplained persistent AFP should lead to family study and/or AFP gene promoter sequencing to avoid inappropriate explorations and treatment decisions.

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results